PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Patients are opting in for 10 years of breast cancer treatment

Nearly two-thirds of higher-risk patients opted to continue endocrine therapy beyond initial 5 years, study finds

2025-06-09
(Press-News.org) ANN ARBOR, Michigan — As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it.

 

In a study of 591 women with early stage breast cancer who completed five years of endocrine therapy, 47% decided to continue the treatment. Patients with stage 2 disease were more likely to continue, with 62% agreeing, compared to 39% of patients with stage 1 cancer.

 

The study, led by researchers at the University of Michigan Rogel Cancer Center and Stanford Medicine, was published in the Journal of the National Cancer Institute.

 

Endocrine therapy includes tamoxifen or aromatase inhibitors, which are designed to interfere with estrogen signaling in breast cancer that’s fueled by estrogen or progesterone. It’s taken daily as a pill. Initially, guidelines recommended five years of endocrine therapy. But recent studies have shown benefit in continuing treatment for 10 years, especially for stage 2 breast cancer.

 

“Endocrine therapy is less intensive than surgery, chemotherapy or radiation treatment. But the fact that it lasts five years – or now 10 years – can be challenging. It was encouraging to see that more than half of the higher-risk stage 2 patients chose to continue the therapy beyond five years,” said co-senior study author Lauren Wallner, Ph.D., M.P.H., associate professor of general medicine and epidemiology at the University of Michigan.

 

Researchers sent follow-up questionnaires to women diagnosed with stage 1 or 2 breast cancer who had previously participated in the iCanCare study, a longitudinal survey of women with early stage breast cancer and their physicians. The follow-up targeted women who were about six years post-diagnosis, which is the time they would have finished or nearly finished the first five years of endocrine therapy. Of this group, 557 responded.

 

Patients who said they planned to continue treatment were younger and more likely to have received chemotherapy. Women who reported discussing the decision with their primary care doctor were also more likely to continue treatment.

 

The factors that had the most impact on a patient’s decision were their oncologist’s recommendation, worry about recurrence and a desire for the most extensive treatment possible.

 

The guidelines for endocrine therapy are continuing to evolve, but research suggests stronger benefit in 10 years of therapy for patients with stage 2 cancer than for low-risk stage 1 disease.

 

“The magnitude of additional estimated benefit varies and may potentially be greater for patients with higher-risk cancer. But in general, extending endocrine therapy represents an action patients can take that aims to reduce their recurrence risk, and for some patients that is powerful,” said study first author Allison W. Kurian, M.D., M.Sc., professor of medicine and of epidemiology and population health at Stanford.

 

The role of both the oncologist and the primary care physician in patients’ decision-making suggests the need for ongoing collaboration and assessments of treatment risks and benefits.

 

“This study emphasizes the importance of a shared decision-making approach among cancer patients, oncologists and primary care physicians that may need to be revisited over time. This type of shared decision-making is becoming more common – and more necessary – as patients have more treatment options and decisions to make,” said co-senior author Sarah Hawley, Ph.D., M.P.H., Maisel Research Professor of Cancer Control and Population Science at the Rogel Cancer Center.

 

Additional authors: Allison K.C. Furgal, Ph.D.; Archana Radhakrishnan, M.D., M.H.S.; Christine M. Veenstra, M.D., MSHP; Paul Abrahamse, M.A.; Kevin C. Ward, Ph.D., M.P.H.; Ann S. Hamilton, Ph.D.; Timothy P. Hofer, M.D., M.Sc.; Steven J. Katz, M.D., M.P.H.

 

Funding for this work is from American Cancer Society, National Cancer Institute grants P01 CA163233, P30 CA046592

 

This work was supported by these Rogel Cancer Center Shared Resources: Cancer Data Science

 

Disclosure: None relevant to this research

 

Paper cited: “Extended endocrine therapy use and decision-making after breast cancer diagnosis,” Journal of the National Cancer Institute. DOI: 10.1093/jnci/djaf076

 

Resources:

University of Michigan Rogel Cancer Center, www.rogelcancercenter.org

Michigan Medicine Cancer AnswerLine, 800-865-1125

 

# # #

 

END



ELSE PRESS RELEASES FROM THIS DATE:

Center for Bioenergy Innovation taps Cregger, Eckert as chief science officers

2025-06-09
The Center for Bioenergy Innovation, or CBI, at the Department of Energy’s Oak Ridge National Laboratory has promoted Melissa Cregger and Carrie Eckert to serve as chief science officers, advancing the center’s mission of innovations for new domestic biofuels, chemicals and materials. Cregger will oversee CBI’s development of resilient, high-yielding, non-food feedstock crops, while Eckert will guide the center’s research on cost-effective methods to break down and convert plant biomass into valuable fuels and products. Brian Davison, chief scientist for biotechnology at ORNL and formerly chief science officer for the center, ...

Anthropologists map Neanderthals’ long and winding roads across Europe and Eurasia

2025-06-09
Recent scholarship has concluded that Neanderthals made a second major migration from Eastern Europe to Central and Eastern Eurasia between 120,000 and 60,000 years ago. But the routes they took have long been a mystery—primarily because there are few archaeological sites connecting the two regions.  In a new analysis, a team of anthropologists—using computer simulations—has offered a map of possible pathways, which concludes Neanderthals likely used river valleys as natural highways and traveled during warmer periods to move approximately 2,000 miles (3,250 km) in less than 2,000 years.  “Our findings show that, despite obstacles like mountains ...

Stress genes clear dead cells, offering disease insights

2025-06-09
A new study from The University of Texas at Arlington details a novel strategy for how the body clears out dead cells during stress, revealing unexpected roles for well-known stress-response genes—a discovery that could help scientists better understand diseases affecting the immune system, brain and metabolism.   “The body is constantly creating new cells and removing old cells once they die,” said Aladin Elkhalil, lead author of the study and a third-year doctoral student in the lab of Piya Ghose, ...

Healthy sleep patterns in adolescence predict better cardiovascular health in the future

2025-06-09
DARIEN, IL – A new study to be presented at the SLEEP 2025 annual meeting found that teens with earlier, more efficient, and less variable sleep patterns at age 15 had better cardiovascular health at age 22. Results show that several healthy sleep habits at age 15 predicted a higher (better) cardiovascular health score at age 22: falling asleep and waking up earlier, spending a lower percentage of time in bed awake, and having lower variability in total sleep time and sleep onset. In contrast, average total sleep time did not predict future cardiovascular health. Results were adjusted for potential confounders ...

A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer

2025-06-09
Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we now call precision oncology, characterizing the molecular features of a patient's specific cancer to determine the most effective treatment. Prostate cancer is considered the most prevalent tumor among men, and it typically has a high cure rate. As such, although many men will be diagnosed with this cancer, the majority will be cured. "However, when we refer ...

Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from major world religions

2025-06-09
A new study in the peer-reviewed journal Psychedelic Medicine showed that psilocybin administration in a sample of clergy from major world religions increased multiple domains of overall psychological well-being, including positive changes in religious attitudes and behavior as well as effectiveness in their vocation as a religious leader. Click here to read the article now. The late Roland Griffiths, of Johns Hopkins University, along with Stephen Ross and Anthony Bossis, from New York University Grossman School ...

Investigating how stress may cause sleep and memory deficits

2025-06-09
Stress worsens sleep quality and can impair memory. Shinjae Chung, from the University of Pennsylvania, led a study to explore a neural pathway in male mice that stress may influence to cause sleep and memory disturbances.   In their JNeurosci paper, the researchers artificially activated neurons in the paraventricular nucleus of the hypothalamus (PVN) that were previously linked to stress. This experimental manipulation made mice sleep less and impaired how well mice performed in a memory task. Notably, when mice were stressed, artificially inhibiting these PVN neurons reduced stress-related memory ...

Researchers find thousands of pediatric firearm deaths linked to more permissive state gun laws

2025-06-09
Guns are now the leading cause of death for youth in the United States. Researcher from Mass General Brigham investigated whether firearm mortality rates among U.S. children ages 0-17 changed in the 13 years following a 2010 Supreme Court ruling that applied the Second Amendment to state and local governments. In states with the most permissive firearm laws, they found evidence of 6,029 more pediatric deaths due to firearms than would have been expected based on the existing demographic trends—and more than 1,400 excess ...

Landmark test for coeliac disease promises to take away the pain of diagnosis

2025-06-09
Imagine having to eat something that makes you sick – just to see what’s making you ill in the first place.  That’s the harsh reality of current diagnostic tests for coeliac disease, which require people to eat large amounts of gluten for weeks in order to get an accurate diagnosis. But this painful process could soon be a thing of the past, with WEHI researchers and industry partner Novoviah Pharmaceuticals developing a world-first blood test that can identify the condition in patients – even when they’re on gluten-free diets.   At a glance New clinical research published in the high-impact ...

A recipe for success: beefing up the taste of cultured meat with amino acids

2025-06-09
Tokyo, Japan – Across the world the demand for meat is growing, despite associated environmental and animal welfare costs. Although lab-grown – or cultured – meat could be part of the answer, scientists have yet to perfect one crucial detail: the taste. In an article to be published in Food Chemistry, researchers from the Institute of Industrial Science, The University of Tokyo, have measured and found a way to control the key amino acids responsible for flavor in a step toward making cultured meat taste just like the real thing. The push toward cultured meat has been adopted because conventional production is not a sustainable solution for ...

LAST 30 PRESS RELEASES:

From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New method to study catalysts could lead to better batteries

Current Molecular Pharmacology impact factor rises to 2.9, achieving Q2 ranking in the Pharmacology & Pharmacy category in 2024 JCR

More time with loved ones for cancer patients spared radiation treatment

New methods speed diagnosis of rare genetic disease

Genetics of cardiomyopathy risk in cancer survivors differ by age of onset

Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism

Targeting fusion protein’s role in childhood leukemia produces striking results

Clear understanding of social connections propels strivers up the social ladder

New research reveals why acute and chronic pain are so different – and what might make pain last

Stable cooling fostered life, rapid warming brought death: scientists use high-resolution fusuline data reveal evolutionary responses to cooling and warming

New research casts doubt on ancient drying of northern Africa’s climate

Study identifies umbilical cord blood biomarkers of early onset sepsis in preterm newborns

AI development: seeking consistency in logical structures

Want better sleep for your tween? Start with their screens

Cancer burden in neighborhoods with greater racial diversity and environmental burden

Alzheimer disease in breast cancer survivors

New method revolutionizes beta-blocker production process

Mechanism behind life-threatening cancer drug side-effect revealed

Weighted vests might help older adults meet weight loss goals, but solution for corresponding bone loss still elusive

Scientists find new way to predict how bowel cancer drugs will stop working – paving the way for smarter treatments

Breast cancer patients’ microbiome may hold key to avoiding damaging heart side-effects of cancer therapies

Exercise-induced protein revives aging muscles and bones

American College of Cardiology issues guidance on weight management drugs

Understanding the effect of bedding on thermal insulation during sleep

Cosmic signal from the very early universe will help astronomers detect the first stars

With AI, researchers find increasing immune evasion in H5N1

Study finds hidden effects of wildfires on water systems

Airborne fungal spores may help predict COVID-19 & flu surges

[Press-News.org] Patients are opting in for 10 years of breast cancer treatment
Nearly two-thirds of higher-risk patients opted to continue endocrine therapy beyond initial 5 years, study finds